These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

227 related articles for article (PubMed ID: 30868550)

  • 1. Comparative Effectiveness of Abatacept Versus Tumor Necrosis Factor Inhibitors in Patients with Rheumatoid Arthritis Who Are Anti-CCP Positive in the United States Corrona Registry.
    Harrold LR; Litman HJ; Connolly SE; Alemao E; Kelly S; Rebello S; Hua W; Kremer JM
    Rheumatol Ther; 2019 Jun; 6(2):217-230. PubMed ID: 30868550
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Association Between Baseline Anti-cyclic Citrullinated Peptide Antibodies and 6-Month Clinical Response Following Abatacept or TNF Inhibitor Treatment: A Real-World Analysis of Biologic-Experienced Patients with RA.
    Harrold LR; Bryson J; Lehman T; Zhuo J; Gao S; Han X; Schrader A; Rebello S; Pappas DA; Sommers T; Kremer JM
    Rheumatol Ther; 2021 Jun; 8(2):937-953. PubMed ID: 34047953
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effect of Anticitrullinated Protein Antibody Status on Response to Abatacept or Antitumor Necrosis Factor-α Therapy in Patients with Rheumatoid Arthritis: A US National Observational Study.
    Harrold LR; Litman HJ; Connolly SE; Kelly S; Hua W; Alemao E; Rosenblatt L; Rebello S; Kremer JM
    J Rheumatol; 2018 Jan; 45(1):32-39. PubMed ID: 29093151
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Comparative effectiveness of abatacept versus tocilizumab in rheumatoid arthritis patients with prior TNFi exposure in the US Corrona registry.
    Harrold LR; Reed GW; Solomon DH; Curtis JR; Liu M; Greenberg JD; Kremer JM
    Arthritis Res Ther; 2016 Dec; 18(1):280. PubMed ID: 27906048
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Comparative Effectiveness of Abatacept vs. Tofacitinib in Rheumatoid Arthritis Patients who are CCP.
    Harrold LR; Wittstock K; Kelly S; Han X; Shan Y; Guo L; Moore PC; Khaychuk V
    Rheumatol Ther; 2023 Jun; 10(3):575-587. PubMed ID: 36749478
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Comparative effectiveness of abatacept versus TNF inhibitors in rheumatoid arthritis patients who are ACPA and shared epitope positive.
    Harrold LR; Wittstock K; Kelly S; Han X; Zhuo J; Schrader A; Middaugh N; Moore PC; Khaychuk V
    Adv Rheumatol; 2024 Jan; 64(1):10. PubMed ID: 38243281
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Comparative risk of osteoporotic fracture among patients with rheumatoid arthritis receiving TNF inhibitors versus other biologics: a cohort study.
    Shin A; Park EH; Dong YH; Ha YJ; Lee YJ; Lee EB; Song YW; Kang EH
    Osteoporos Int; 2020 Nov; 31(11):2131-2139. PubMed ID: 32514765
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Efficacy of Abatacept Versus Tumor Necrosis Factor Inhibitors in Anti-citrullinated Protein Antibody-Positive Patients with Rheumatoid Arthritis: Results from a Korean Nationwide Biologics Registry.
    Kim MJ; Lee SK; Oh S; Kim HA; Park YB; Lee SS; Shin K
    Rheumatol Ther; 2022 Aug; 9(4):1143-1155. PubMed ID: 35716235
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Baseline Anti-Citrullinated Protein Antibody Status and Response to Abatacept or Non-TNFi Biologic/Targeted-Synthetic DMARDs: US Observational Study of Patients with RA.
    Harrold LR; Connolly SE; Wittstock K; Zhuo J; Kelly S; Lehman T; Shan Y; Rebello S; Guo L; Khaychuk V
    Rheumatol Ther; 2022 Apr; 9(2):465-480. PubMed ID: 34940957
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Alternative tumour necrosis factor inhibitors (TNFi) or abatacept or rituximab following failure of initial TNFi in rheumatoid arthritis: the SWITCH RCT.
    Brown S; Everett CC; Naraghi K; Davies C; Dawkins B; Hulme C; McCabe C; Pavitt S; Emery P; Sharples L; Buch MH
    Health Technol Assess; 2018 Jun; 22(34):1-280. PubMed ID: 29900829
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Real-world Comparative Effectiveness of Tocilizumab Monotherapy vs. Tumor Necrosis Factor Inhibitors with Methotrexate in Patients with Rheumatoid Arthritis.
    Harrold LR; Reed GW; Best J; Zlotnick S; Kremer JM
    Rheumatol Ther; 2018 Dec; 5(2):507-523. PubMed ID: 30293218
    [TBL] [Abstract][Full Text] [Related]  

  • 12. TNFi Cycling Versus Changing Mechanism of Action in TNFi-Experienced Patients: Result of the Corrona CERTAIN Comparative Effectiveness Study.
    Curtis JR; Kremer JM; Reed G; John AK; Pappas DA
    ACR Open Rheumatol; 2022 Jan; 4(1):65-73. PubMed ID: 34741435
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Risk of serious infections in tocilizumab versus other biologic drugs in patients with rheumatoid arthritis: a multidatabase cohort study.
    Pawar A; Desai RJ; Solomon DH; Santiago Ortiz AJ; Gale S; Bao M; Sarsour K; Schneeweiss S; Kim SC
    Ann Rheum Dis; 2019 Apr; 78(4):456-464. PubMed ID: 30679153
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A window of opportunity for abatacept in RA: is disease duration an independent predictor of low disease activity/remission in clinical practice?
    Harrold LR; Litman HJ; Connolly SE; Kelly S; Hua W; Alemao E; Rosenblatt L; Rebello S; Kremer JM
    Clin Rheumatol; 2017 Jun; 36(6):1215-1220. PubMed ID: 28251392
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The comparative effectiveness of abatacept versus anti-tumour necrosis factor switching for rheumatoid arthritis patients previously treated with an anti-tumour necrosis factor.
    Harrold LR; Reed GW; Kremer JM; Curtis JR; Solomon DH; Hochberg MC; Greenberg JD
    Ann Rheum Dis; 2015 Feb; 74(2):430-6. PubMed ID: 24297378
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Persistence rates of abatacept and TNF inhibitors used as first or second biologic DMARDs in the treatment of rheumatoid arthritis: 9 years of experience from the Rhumadata® clinical database and registry.
    Choquette D; Bessette L; Alemao E; Haraoui B; Postema R; Raynauld JP; Coupal L
    Arthritis Res Ther; 2019 Jun; 21(1):138. PubMed ID: 31171024
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Comparison of infection-related hospitalization risk and costs in tumor necrosis factor inhibitor-experienced patients with rheumatoid arthritis (RA) treated with abatacept or other targeted disease-modifying anti-rheumatic drugs (tDMARDs).
    Paul D; Patil D; McDonald L; Patel V; Lobo F
    J Med Econ; 2020 Sep; 23(9):1025-1031. PubMed ID: 32427547
    [No Abstract]   [Full Text] [Related]  

  • 18. Impact of anti-citrullinated protein antibody on tumor necrosis factor inhibitor or abatacept response in patients with rheumatoid arthritis.
    Tymms K; Butcher B; Smith T; Littlejohn G; Consortium O
    Eur J Rheumatol; 2021 Apr; 8(2):67-72. PubMed ID: 32966190
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Malignant Neoplasms in Patients With Rheumatoid Arthritis Treated With Tumor Necrosis Factor Inhibitors, Tocilizumab, Abatacept, or Rituximab in Clinical Practice: A Nationwide Cohort Study From Sweden.
    Wadström H; Frisell T; Askling J;
    JAMA Intern Med; 2017 Nov; 177(11):1605-1612. PubMed ID: 28975211
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Comparative effectiveness and safety of rituximab versus subsequent anti-tumor necrosis factor therapy in patients with rheumatoid arthritis with prior exposure to anti-tumor necrosis factor therapies in the United States Corrona registry.
    Harrold LR; Reed GW; Magner R; Shewade A; John A; Greenberg JD; Kremer JM
    Arthritis Res Ther; 2015 Sep; 17(1):256. PubMed ID: 26382589
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.